Trust Co. of Toledo NA OH Sells 3,260 Shares of Pfizer Inc. (NYSE:PFE)

Trust Co. of Toledo NA OH reduced its position in Pfizer Inc. (NYSE:PFE) by 2.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 143,633 shares of the biopharmaceutical company’s stock after selling 3,260 shares during the quarter. Trust Co. of Toledo NA OH’s holdings in Pfizer were worth $3,811,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GHP Investment Advisors Inc. increased its holdings in Pfizer by 5.2% in the 2nd quarter. GHP Investment Advisors Inc. now owns 12,589 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 620 shares in the last quarter. Parallel Advisors LLC increased its position in Pfizer by 19.1% in the 2nd quarter. Parallel Advisors LLC now owns 108,180 shares of the biopharmaceutical company’s stock valued at $3,027,000 after buying an additional 17,370 shares in the last quarter. Thoroughbred Financial Services LLC boosted its holdings in Pfizer by 102.9% in the second quarter. Thoroughbred Financial Services LLC now owns 32,173 shares of the biopharmaceutical company’s stock worth $900,000 after acquiring an additional 16,313 shares in the last quarter. Oppenheimer Asset Management Inc. grew its stake in Pfizer by 9.0% in the second quarter. Oppenheimer Asset Management Inc. now owns 328,170 shares of the biopharmaceutical company’s stock valued at $9,182,000 after acquiring an additional 27,178 shares during the period. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Pfizer by 2.4% during the second quarter. Envestnet Asset Management Inc. now owns 10,260,067 shares of the biopharmaceutical company’s stock valued at $287,077,000 after acquiring an additional 238,850 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 11.11 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.06% of the company’s stock.

Pfizer Price Performance

PFE stock traded down $0.20 during mid-day trading on Monday, hitting $26.52. The company had a trading volume of 7,651,801 shares, compared to its average volume of 31,469,996. The company has a market capitalization of $150.29 billion, a price-to-earnings ratio of 35.84, a P/E/G ratio of 0.63 and a beta of 0.64. The company has a 50-day moving average price of $26.18 and a 200 day moving average price of $28.04. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same period last year, the firm posted ($0.17) earnings per share. Pfizer’s revenue for the quarter was up 31.2% compared to the same quarter last year. On average, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.49%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is presently 232.43%.

Analyst Ratings Changes

Several research firms have recently issued reports on PFE. Citigroup assumed coverage on shares of Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price for the company. Wolfe Research started coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Finally, Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $32.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.